Inactivation of Human Factor VIII by Granulocyte Proteases

Summary

The effect of human granulocyte proteases and related pancreatic enzymes on the procoagulant (VIII:C) and the von Willebrand (VIIIR:WF) activities of factor VIII was investigated. VIII:C appeared to be several hundred times more sensitive towards granulocyte enzymes than VIIIR: WF. The elastase-like protease (ELP) decreased both activities of factor VIII more effectively than the chymotrypsin-like enzyme (CLP). ELP increased co-operatively the inactivating effect of CLP. In the presence of a CLP-ELP mixture in a ratio of 3:1, the rate of inactivation of VIII:C was seven times as high as that with CLP alone.

Factor VIII was more resistant towards the damaging effect of pancreatic enzymes. The rate of inactivation of VIII: C was about a thousand times and that of VIIIR:WF about a hundred times lower than those measured with the related granulocyte enzymes of the same proteolytic activity. The sensitivity of VIII: C towards proteolysis was not as pronounced with pancreatic enzymes as with granulocyte proteases.

Our data suggest that, even though CLP and ELP are called "-like" enzymes, the specificity of granulocyte proteases is not identical with that of the pancreatic enzymes. The extreme sensitivity of VIII: C for granulocyte proteases may bring about blood coagulation disorders in certain pathological conditions.

Keywords

Factor VHI/procoagulant activity - Factor VIII/von Willebrand activity - Granulocyte proteases

• References

• 1 Weiss HJ, Kochwa S. Molecular forms of antihemophilic globulin in plasma, cryoprecipitate and after thrombin activation. Br J Haemat 1970; 18: 89-100
• 2 Rick ME, Hoyer LW. Immunologic studies of antihaemophilic factor (AHF, Factor VIII). V. Immunologic properties of AHF subunits produced by salt dissociation. Blood 1973; 42: 737-747
• 3 Poon MC, Ratnoff OD. Evidence that functional subunits of antihemophilic factor (factor VIII) are linked by noncovalent bonds. Blood 1976; 48: 87-94
• 4 Elödi S, Váradi K. Optimization of conditions for the catalytic effect of the factor IXa – factor VIII complex. Probable role of the complex in the amplification of blood coagulation. Thromb Res 1979; 15: 617-629
• 5 McKee PA, Andersen JC, Switzer ME. Molecular structural studies of human factor VIII. Ann N Y Acad Sci 1975; 240: 8-33
• 6 Legaz ME, Weinstein MJ, Heldebrandt M, Davie EW. Isolation, subunit structure and proteolytic modification of bovine factor VIII. Ann N Y Acad Sci 1975; 240: 43-61
• 7 Oronsky AL, Buermann CV. Phagocytic release of human leukocyte neutral proteases. Analysis of cartilage degradation products. Arch Biochem Biophys 1976; 176: 539-546
• 8 Ohlsson K, Olsson I. The extracellular release of granulocyte collagenase and elastase during phagocytosis and inflammatory processes. Scand J Haematol 1977; 19: 145-152
• 9 Schmidt W, Egbring R, Haveman K. Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors. Thromb Res 1975; 6: 315-326
• 10 Norman PS. Studies on the plasmin system. J Exper Med, 1957; 106: 423-437
• 11 Henson PM. The immunologic release of constituents from neutrophyl leukocytes. J Immunol 1971; 107: 535-1546
• 12 Chordiker WB, Bock GN, Vaughan JH. Isolation of human PMN leukocytes and granules. Observation on early blood dilution and heparin. J Lab Clin Med 1968; 71: 9-19
• 13 Feinstein G, Janoff A. A rapid method for purification of human granulocyte cationic neutral proteases: purification and characterization of human granulocyte chymotrypsin-like enzyme. Biochim Biophys Acta 1975; 403: 477-492
• 14 Baugh RJ, Travis J. Human leukocyte granule elastase: rapid isolation and characterization. Biochemistry 1976; 15: 836-841
• 15 Newman J, Johnson AJ, Karpatkin MH, Puszkin S. Method for the production of clinically effective intermediate and high-purity factor VIII concentrates. Br J Haematol 1971; 21: 1-20
• 16 Van Mourik JA, Mochtar IA. Purification of human antihaemophilic factor (factor VIII) by gel chromatography. Biochim Biophys Acta 1970; 221: 677-679
• 17 Elödi S, Váradi K, Hollán SR. Some sources of error in the one-stage assay of factor VIII. Haemostasis 1978; 7: 1-9
• 18 MacFarlane DE, Stibbe J, Kirby EP, Zucker MB, Grant RA, McPherson J. A method for assaying von Willebrand factor (Ristocetin cofactor). Thromb Diath Haemorrh 1975; 34: 306-308
• 19 Stibbe J, Kirby EP. The influence of Haemacell, fibrinogen and albumin on Ristocetin-induced platelet aggregation. Relevance to the quantitative measurement of Ristocetin Cofactor. Thromb Res 1976; 8: 151-165
• 20 Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem, 1951; 193: 265-275
• 21 Sodetz JM, Paulson JC, Pizzo SV, McKee PA. Carbohydrate of human factor VIII (von Willebrand factor). Impairment of function by removal of specific galactose residues. J Biol Chem 1978; 253: 7202-7206
• 22 Guisasola JA, Cockburn CG, Hardisty RM. Plasmin digestion of factor VIII: characterization of the breakdown products with respect to antigenicity and von Willebrand activity. Thromb. Haemost 1978; 40: 302-315
• 23 Gralnick HR, Morisato DK. The importance of carbohydrate moiety of the factor VIII (von Willebrand factor) protein in binding to and causing agglutination of human platelets. Thromb Haemost 1979; 42: 372 Abstr. VIIth International Congress on Thrombosis and Haemostasis, London, 15-20, July 1979
• 24 Blow AM J. Action of human lysosomal elastase on the oxidized B chain of insulin. Biochem J 1977; 161: 13-16
• 25 Blow AM J, Barrett AJ. Action of human cathepsin G on the oxidized B chain of insulin. Biochem J 1977; 161: 17-19
• 26 Taylor JC, Crawford IP. Purification and preliminary characterization of human leukocyte elastase. Arch Biochem Biophys 1975; 169: 91-101
• 27 Egbring R, Schmidt W, Fuchs G, Haveman K. Demonstration of granulocytic proteases in plasma of patients with acute leukemia and septicemia with coagulation defects. Blood 1977; 49: 219-231